Why endocrine tumours do not carry KRAS mutations: menin blocks the proliferative arm of RAS
also called menin K-RAS RASSF1A · menin MAPK endocrine · GLP1 agonist menin inhibitor synergy
In hormone cells, the famous cancer gene KRAS actually slows growth instead of speeding it, because menin blocks the growth-promoting branch of its signal. Remove menin and the same signal flips to promoting growth - and a diabetes drug that would do nothing on its own then starts making the cells divide.
The same thing, for a scientist
Chamberlain and colleagues asked why activating KRAS mutations, universal in pancreatic ductal adenocarcinoma, are never found in pancreatic endocrine tumours. In pancreatic endocrine cells K-RAS **suppresses** rather than promotes growth; the suppression depends on the antiproliferative RAS effector RASSF1A and on menin's blockade of the proproliferative RAF/MAPK arm. The direct pharmacological consequence, reported in the same paper: a GLP1 agonist, which stimulates ERK1/2 phosphorylation, did **not** affect endocrine-cell proliferation by itself, but **synergistically enhanced proliferation when combined with a menin inhibitor**; conversely MAPK inhibition is synthetically lethal in the menin-loss setting [E1].
The combination result is the one that should worry a paediatric oncologist
A GLP1 receptor agonist alone: no proliferative effect on endocrine cells. A menin inhibitor alone: modest. Together: synergistic proliferation 1. Two separate lines in this beat converge on that sentence:
- menin represses GLP1R, so a menin inhibitor raises the receptor [see
mechanism-menin-prmt5-represses-glp1r-transcription]; - menin inhibition raises circulating GLP-1 from gut L cells [see
mechanism-menin-inhibition-raises-gut-glp1-secretion].
So a menin inhibitor plausibly supplies both halves of its own synergistic combination: more ligand, more receptor, and the MAPK brake removed. Nobody has tested whether that self-assembling combination occurs at clinical exposures, and it is the single most specific mechanistic hazard this beat has found.
The upside of the same finding
The authors offer it in both directions explicitly: as a strategy for regenerating beta cells in diabetes, and as a route to targeting menin-sensitive endocrine tumours by MAPK inhibition. It also explains a genuine epidemiological fact - the absence of KRAS mutation from pancreatic endocrine tumours - which is the kind of independent corroboration a mechanism rarely gets.
| finding | K-RAS is antiproliferative in pancreatic endocrine cells; menin blocks the RAF/MAPK arm |
|---|---|
| pharmacological interaction | GLP1 agonist + menin inhibitor = synergistic endocrine-cell proliferation |
| synthetic lethality | MAPK inhibition in the menin-loss setting |
| clinical compounds tested | none |
effectors
[ "RASSF1A", "RAF/MAPK" ]
- A menin inhibitor may create both halves of a proliferative synergy in endocrine tissue: it raises GLP-1, raises GLP1R, and removes the menin brake on MAPK output.
- GLP-1 receptor agonists are now extremely widely prescribed; a survivor of infant leukaemia treated with a menin inhibitor may meet one later in life, and the interaction has never been assessed.
- The same paper's synthetic-lethality result means MAPK inhibition may be needed to make chronic menin inhibition safe in endocrine tissue - which would change the combination strategy in leukaemia for a non-leukaemic reason.
- Does a menin inhibitor at clinical exposure reconstitute its own synergistic combination by simultaneously raising GLP-1 and GLP1R while removing the MAPK brake?
- Is there any child who has received a menin inhibitor and a GLP-1 receptor agonist concurrently, and is there a registry that could find them?
- Would adding a MEK inhibitor - already combined with menin inhibitors in RAS-mutant leukaemia trials - protect the endocrine pancreas as a side effect?
- E1moderate confidence 3 of 5: One strong study, or several smaller consistent ones.paper
Menin blocks the RAF/MAPK proliferative arm of K-RAS in pancreatic endocrine cells, and a GLP1 agonist synergises with a menin inhibitor to drive endocrine-cell proliferation.
Menin determines K-RAS proliferative outputs in endocrine cells. · Chamberlain CE, Scheel DW, McGlynn K, Kim H, Miyatsuka T, Wang J, et al. · Journal of Clinical Investigation 2014What this evidence cannot show
Mouse and cell-based endocrine systems; the menin inhibitor is a tool compound and the synergy is an in-vitro/ex-vivo proliferation readout, not an in-vivo tumour endpoint; the GLP1 agonist is not specified as a clinically used molecule in the abstract.
Evidence that argues against this (1)
- In the one in-vivo pharmacological experiment with an islet endpoint, three months of a menin inhibitor produced compensatory proliferation with improved glucose handling and no reported neoplasia - the synergy has not been shown to translate into a tumour phenotype in a whole animal. Ma J et al. 2021
- depends on →Menin represses GLP1R - the receptor a whole class of diabetes drugs exists to switch on
The reported GLP1-agonist x menin-inhibitor proliferative synergy is amplified by menin's own repression of GLP1R: the drug supplies the receptor arm of its own combination
and the ligand arm: menin inhibition raises circulating GLP-1 from gut L cells, completing the synergistic pair in a single-agent exposure